Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Evoke Pharma (NASDAQ:EVOK) Expands GIMOTI Access via Omnicell and Brentwood Deals

Evoke Pharma announced a set of distribution agreements intended to materially broaden patient access to GIMOTI® nasal spray, the only FDA-approved intranasal treatment for adults with acute and recurrent diabetic gastroparesis. The company said strategic arrangements with Omnicell (NASDAQ: OMCL) and Brentwood Pharmacy will …

Team Kalkine | 26 August 2025

Marker Therapeutics (NASDAQ:MRKR) Posts 66% ORR in Phase 1 APOLLO Study

Marker Therapeutics reported encouraging early efficacy and tolerability data from its Phase 1 APOLLO study of MT-601, a Multi-Antigen Recognizing T cell product, in relapsed lymphoma. The trial enrolled 24 B-cell lymphoma patients across seven U.S. clinical sites with dose levels spanning 100×10^6 to …

Team Kalkine | 26 August 2025

IBM (NYSE: IBM) and AMD (NASDAQ: AMD) Announce Quantum-Centric Supercomputing Collaboration

IBM and AMD have announced a collaboration intended to explore quantum-centric supercomputing architectures that combine IBM’s quantum platforms with AMD’s CPUs, GPUs and FPGAs. The stated aim is to accelerate algorithm development for hybrid quantum-classical workflows and to support IBM’s longer-term objective of delivering …

Team Kalkine | 26 August 2025

Centrus Energy (NYSE: LEU) MOU with KHNP and POSCO Signals Potential U.S.-Korea Nuclear Tie-up

Centrus Energy (NYSE: LEU) announced a Memorandum of Understanding with Korea Hydro & Nuclear Power (KHNP) and POSCO International to explore possible Korean investment in expanding Centrus’ uranium enrichment plant in Piketon, Ohio. The agreement, signed with government officials present, frames a pathway for …

Team Kalkine | 26 August 2025

Serina Therapeutics (NYSE American: SER) — FDA Feedback Advances SER-252 Development Pathway

Serina Therapeutics (NYSE American: SER) said the U.S. Food and Drug Administration gave constructive feedback that supports advancing SER-252, a POZ-enabled apomorphine formulation aimed at treating advanced Parkinson’s disease, via a 505(b)(2) NDA pathway. The company plans to launch a registrational clinical development program …

Team Kalkine | 26 August 2025

Porch Group (NASDAQ: PRCH) — Zacks Lowers Rating to Hold

Porch Group (NASDAQ: PRCH) saw a notable shift in sell-side sentiment this month after the company reported second-quarter results and updated FY-2025 guidance. While some analysts pushed price objectives higher, Zacks Research moved its recommendation the other way — downgrading the stock from a …

Aditi Sarkar | 26 August 2025

Korean Air Commits to 103-Aircraft Purchase from Boeing (NYSE: BA)

Boeing (NYSE: BA) this week secured a landmark commitment from Korean Air for 103 aircraft, marking the carrier’s largest single order and Boeing’s largest widebody commitment from an Asian airline. Signed during the Korea–U.S. Business Roundtable, the agreement spans long-range and single-aisle types: 20 …

Team Kalkine | 26 August 2025

Markets Brace for Key Earnings, Inflation Data as Fed Signals Rate Cuts

Index Update:Markets are focused on key earnings this week, with Nvidia and CrowdStrike reporting Wednesday, followed by Dell and Marvell on Thursday, and on Friday’s release of the Fed’s preferred inflation gauge, the PCE index. Wall Street rallied strongly Friday after Fed Chair Powell …

Team Kalkine | 25 August 2025

Hamilton Insurance Group (NYSE: HG): Analysts Average ‘Hold’ with Mixed Targets

Hamilton Insurance Group Ltd. (NYSE: HG) currently carries an average recommendation of “Hold” from eight sell-side firms that have published ratings within the past year. The group’s average 12-month price target sits at USD 25.4286, indicating modest upside from recent trading levels but little …

Aditi Sarkar | 25 August 2025

Genpact (NYSE: G): Consensus ‘Hold’ as Targets Cluster Near USD 52

Genpact Limited (NYSE: G) currently carries a consensus recommendation of “Hold” from seven research firms tracked by MarketBeat. The distribution tilts neutral—four “hold” ratings and three “buy”—with an average 12-month price objective of USD 52.2857. The cluster suggests modest expected appreciation but little agreement …

Aditi Sarkar | 25 August 2025
Support

Hi! How can we help you today?

Loading…